

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Medlab Clinical Limited
ABN	51 169 149 071

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sean Michael Hall
Date of last notice	08 November 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (Including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	a) Sean Michael Hall b) Comdox No 229 Pty Ltd
Date of change	30 March 2022 (settlement date)
No. of securities held prior to change	a) 58,025,555 Ordinary shares b) 500,000 Ordinary Shares c) 4,000,000 unlisted \$0.20 options expiring 31 October 2022
Class	Ordinary shares
Number acquired	95,744 Ordinary shares
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$8,997.50

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	a) 58,121,299 Ordinary shares b) 500,000 Ordinary Shares c) 4,000,000 unlisted \$0.20 options expiring 31 October 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	